TopAlliance Biosciences is a next-generation biopharmaceutical company dedicated to the discovery and development of innovative drugs towards clinical research and commercialization. Since our establishment in 2012, we have leveraged our advanced discovery platforms, research tools and globally integrated R&D processes, in developing a portfolio of drug candidates across broad therapeutics areas.
Our parent company, Shanghai Junshi Biosciences, is the first biopharmaceutical company in China to obtain approval of anti-PD-1 monoclonal antibody and the first company to obtain approval for clinical trial for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody among the Chinese companies.
Our flagship therapy TUOYI ( Toripalimab) – an anti-PD-1 monoclonal antibody injection), the first product marketed by the Company, has delivered impressive clinical data, and has shown satisfying efficacy and safety on various indications. We are aiming to bring these novel medicines to the U.S. patient population and countries across the globe.
